Researchers compiled antiviral MERS-CoV treatment guidelines based on the 2015 South Korea outbreak response experience of treating patients with MERS in an effort to achieve a more effective MERS treatment in the future.
This guidance reflects current understanding of MERS-CoV related to IPC and uses revised case definitions. The guidance is intended for health-care workers (HCWs), health-care managers, and IPC teams.
Since coronaviruses similar to MERS-CoV and SARS-CoV have been detected in bats without symptoms, it follows that bats must employ an immune response to survive infections.
The Saudi Arabia Ministry of Health reported two deaths due to Middle East respiratory syndrome (MERS), bringing the total number of deaths to 707 since June 2014.
Saudi Arabia has reported three more Middle East respiratory syndrome (MERS) cases in men from Riyadh, while Oman has reported its second infection of 2017.
Saudi Arabia has reported four new MERS-CoV, three of them involving camel contact.
The epidemic level of MERS-CoV infection was examined in Saudi Arabia by the Susceptible-Infectious-Recovered model using a Bayesian approach for estimation of time dependent reproduction number across a two-year interval.
Since 2012, a total of 2,090 laboratory-confirmed Middle East respiratory syndrome (MERS) cases worldwide have been reported.
MERS coronavirus appears to have emerged in humans in Saudi Arabia in 2012, but has been traced back in camels to at least 1983.
Representatives from the Ministries of Health and Ministries of Agriculture of affected and at-risk countries have agreed on next steps to accelerate the response to the threat posed by Middle East respiratory syndrome coronavirus (MERS-CoV).